Why the study?
Does the sirolimus-eluting stent reduce restenosis and lesion revascularization compared to bare metal stents and balloon angioplasty in patients requiring coronary revascularization?
Does the sirolimus-eluting stent reduce restenosis and lesion revascularization compared to bare metal stents and balloon angioplasty in patients requiring coronary revascularization?
This review highlights that sirolimus-eluting stents significantly lower restenosis and revascularization rates compared to bare metal stents across various lesion types and patient populations.
Supports sirolimus-eluting stents to curb restenosis; leaves open need for updated randomized comparisons.
The sirolimus-eluting stent (SES) Cypher was the first commercially available drug-eluting stent. The use of this stent has resulted in significantly lower rates of restenosis and lesion revascularization compared to bare metal stents and balloon angioplasty. In this review, angiographic and clinical outcomes in patients treated with SES are compared to those treated with bare metal stents and other drug-eluting stents. Furthermore, efficacy and safety outcomes of SES in complex lesions (left main stenosis, bifurcation lesions, chronic total occlusions, long lesions and small vessels) and high risk populations (diabetes and acute myocardial infarction) are presented.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: